Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 1
1979 1
1992 1
2002 2
2003 3
2004 4
2005 1
2014 4
2020 3
2021 5
2022 1
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Results by year

Filters applied: . Clear all
Page 1
Aprotinin-Drug against Respiratory Diseases.
Ivachtchenko AV, Ivashchenko AA, Shkil DO, Ivashchenko IA. Ivachtchenko AV, et al. Among authors: ivashchenko aa. Int J Mol Sci. 2023 Jul 6;24(13):11173. doi: 10.3390/ijms241311173. Int J Mol Sci. 2023. PMID: 37446350 Free PMC article. Review.
Reply to Krishna Prabha et al.
Ivashchenko AA, Savchuk NP, Yakubova EV, Ivachtchenko AV. Ivashchenko AA, et al. Clin Infect Dis. 2021 Aug 2;73(3):e848-e849. doi: 10.1093/cid/ciaa1606. Clin Infect Dis. 2021. PMID: 33099607 No abstract available.
Antiviral susceptibility of clade 2.3.4.4b highly pathogenic avian influenza A(H5N1) viruses isolated from birds and mammals in the United States, 2022.
Nguyen HT, Chesnokov A, De La Cruz J, Pascua PNQ, Mishin VP, Jang Y, Jones J, Di H, Ivashchenko AA, Killian ML, Torchetti MK, Lantz K, Wentworth DE, Davis CT, Ivachtchenko AV, Gubareva LV. Nguyen HT, et al. Among authors: ivashchenko aa. Antiviral Res. 2023 Sep;217:105679. doi: 10.1016/j.antiviral.2023.105679. Epub 2023 Jul 24. Antiviral Res. 2023. PMID: 37494978 Free PMC article.
Effect of Aprotinin and Avifavir® Combination Therapy for Moderate COVID-19 Patients.
Ivashchenko AA, Azarova VN, Egorova AN, Karapetian RN, Kravchenko DV, Krivonos NV, Loginov VG, Poyarkov SV, Merkulova EA, Rosinkova OS, Savchuk NP, Topr MA, Simakina EN, Yakubova EV, Ivachtchenko AV. Ivashchenko AA, et al. Viruses. 2021 Jun 27;13(7):1253. doi: 10.3390/v13071253. Viruses. 2021. PMID: 34199134 Free PMC article.
Property-based design of GPCR-targeted library.
Balakin KV, Tkachenko SE, Lang SA, Okun I, Ivashchenko AA, Savchuk NP. Balakin KV, et al. Among authors: ivashchenko aa. J Chem Inf Comput Sci. 2002 Nov-Dec;42(6):1332-42. doi: 10.1021/ci025538y. J Chem Inf Comput Sci. 2002. PMID: 12444729
AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial.
Ivashchenko AA, Dmitriev KA, Vostokova NV, Azarova VN, Blinow AA, Egorova AN, Gordeev IG, Ilin AP, Karapetian RN, Kravchenko DV, Lomakin NV, Merkulova EA, Papazova NA, Pavlikova EP, Savchuk NP, Simakina EN, Sitdekov TA, Smolyarchuk EA, Tikhomolova EG, Yakubova EV, Ivachtchenko AV. Ivashchenko AA, et al. Clin Infect Dis. 2021 Aug 2;73(3):531-534. doi: 10.1093/cid/ciaa1176. Clin Infect Dis. 2021. PMID: 32770240 Free PMC article. Clinical Trial.
29 results